Proliferative Diabetic Retinopathy Market is Poised to Reach Roughly US$ 1,000 Million by 2026-End


Free Press Release DB | Press Release Date : May 14, 2018  Download


Revenues from treatment of proliferative diabetic retinopathy around the world are poised to reach roughly US$ 1,000 Mn by 2026-end.


 Companies in the global proliferative diabetic retinopathy market are employing strategic initiatives that include product development, geographical expansion, acquisitions, and mergers. These strategies are likely to aid the market players in advancing their businesses and increasing their market footprint. For example, ThromboGenics initiated partnership with Novartis (Alcon) for assisting in commercialization and marketing activities of JETREA beyond the U.S.

 

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40637

 

On similar lines, Alimera initiated sales of ILLUVEN in the U.K. and Germany, in a bid to foray the European market. The initiative was primarily aimed at tapping new markets and boosting revenue generation of the company. A new report of Transparency Market Research has profiles key players making notable contribution to expansion of the global market for proliferative diabetic retinopathy, which include Pfizer, Inc., Genentech, Inc. (Roche Holdings), Merck KGaA, Allergan Plc, Santen Pharmaceutical Co., Ltd., Cipla, Ltd., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.

 

Demand for Proliferative Diabetic Retinopathy Treatment Drugs to Remain Robust

 

According to World Health Organization, number of people affected with diabetes has exceeded 400 Mn, in case of adults, in 2014. Additionally, global prevalence of diabetes doubled, rising at over 8% in adult population. The Department of Assistive and Rehabilitative Services (DARS) has reported that nearly 80% of the diabetic population was affected from diabetic retinopathy in 2013, with a notable portion of this percentile estimated to acquire the proliferative condition. These numbers are further poised to witness a rise in the years to come, driven by unhealthy consumption patterns and comfort-driven lifestyles of consumers worldwide. This will further have a robust impact on demand for treatment drugs apropos to proliferative diabetic retinopathy in the foreseeable future.

 

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40637

 

The report estimates the market to record a splendid rise over the forecast period 2017 to 2026. Nearly US$ 1,000 Mn worth of drugs for treatment of proliferative diabetic retinopathy are anticipated to be sold worldwide by 2026-end. Considered as a serious sight threatening ailment on account of long-term exposure to diabetes, diabetic retinopathy results into progressive retinal damage and affects retinal circulatory system. Extremity of the disease, which may lead to proliferative condition, determines the selection of effective therapeutic measure, thereby entailing requirement for intraocular injections, laser surgery, vitrectomy, or anti-VEGF drug prescriptions.

 

North America to Stay at Forefront of Global Proliferative Diabetic Retinopathy Market

 

In terms of revenues, North America is likely to remain at the forefront of the global proliferative diabetic retinopathy, driven by supportive reimbursement policies offered by the government coupled with greater prevalence of diabetes in the region. Additionally, robust penetration of management drugs such as anti-VEGF drugs viz. Lucentis, Avastin, and Eylea, has further supported revenue generation from treatment of this disease in North America. Europe and Asia-Pacific excluding Japan are also likely to endure as significant revenue contributors to the global proliferative diabetic retinopathy market.

 

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40637

 

Anti-VEGF drugs are likely to remain preferred among various drug class utilized for treatment of proliferative diabetic retinopathy across the globe. Revenues from sales of anti-VEGF drugs are poised to reach approximately US$ 700 Mn by 2026-end. Although corticosteroids’ sales are expected to record an impressive expansion in the market, revenues from this drug class will continue to be sluggish.

 

About Us

 

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

 

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

 

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

 

US Office Contact

 

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com




Contact Person & Company

Name

:

Aman Harper

Company

:

Contact Numbers

Telephone No.

:

Fax No.

:

Handphone No.

:

Website

Website 1

:

Website 2

:

Youtube

:

PR Tags

:

Proliferative Diabetic Retinopathy Market,

Address


Contact The Author



Contact Aman Harper






More Press Release From Author



Urinary Incontinence Treatment Devices Market to Expand at a CAGR of Over 7.0% from 2017 to 2025


Free Press Release DB :

The global urinary incontinence treatment devices market is driven by high prevalence and rapid increase in incidence of urinary incontinence across the globe. --> Read This Press Release !



By : Aman, Harper ( May 14, 2018 )
Category : Healthcare Press Release | Country : United States Press Release




Ophthalmology Surgical Devices Market is Projected to Register a CAGR of 4.0% from 2017 to 2025


Free Press Release DB :

Ophthalmology surgical devices market was valued at around US$ 7.0 Bn in 2016 and is expected to expand at a CAGR of over 4.0% from 2017 to 2025, to reach value of around US$ 11.0 Bn by 2025. --> Read This Press Release !



By : Aman, Harper ( May 14, 2018 )
Category : Healthcare Press Release | Country : United States Press Release




Veterinary Molecular Diagnostics Market to Expand at a CAGR of 8.6% from 2017 to 2025


Free Press Release DB :

Rise in the expenditure on diagnostics, therapeutics, feed additives, and other supplies for companion animals; increase in the number of pet owners and growing urbanization are likely to provide significant opportunities --> Read This Press Release !



By : Aman, Harper ( May 14, 2018 )
Category : Healthcare Press Release | Country : United States Press Release





Read More Articles From Aman Harper



Disclaimer

The author of the press releases are solely responsible for the content of their press releases. Freepressreleasedb.com can't be held liable for the content posted by author. Please check the accuracy of the press release before using the press release. If necessary please contact the author. Thank you.




Report Abuse